Updated Friday, November 24, 2017
 Journal Tools
RSS Feed
Sample Copy
Submit a Manuscript
Contact Us
Subscription
Advertising
Thanking Peer Reviewers
 Language Polishing
Journal of Chinese Integrative Medicine: Volume 10, 2012   Issue 3,  Pages: 318-323

DOI: 10.3736/jcim20120311
Original Clinical Research
Effects of the Chinese patent medicine, Honghua Injection, on platelet glycoprotein Ⅱb/Ⅲa receptors in patients with acute coronary syndrome: a randomized controlled trial
1. Yan-feng Zhu (Department of Vasculocardiology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China )
2. Hai-ming Luo (Department of Vasculocardiology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China E-mail: drluo@medmail.com.cn)
3. Zhong-long Deng (Department of Vasculocardiology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China )
4. De-yu Fu (Department of Vasculocardiology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China )
5. Wang Yao (Department of Vasculocardiology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China )
6. Jian Dai (Department of Vasculocardiology, Yueyang Hospital of Traditional Chinese and Western Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai 200437, China )
BACKGROUND: Glycoprotein (GP) Ⅱb/Ⅲa is an important index for assessing the function of platelets. To investigate the effects of Honghua Injection, a Chinese patent medicine made from extracts of Carthamus tinctorius L, on GP Ⅱb/Ⅲa is a key study in evaluating the inhibition properties of Honghua Injection on platelet aggregation.
OBJECTIVE: To observe the effects of Honghua Injection on platelet GPⅡb/Ⅲa receptors and explore the mechanisms of Honghua Injection in inhibiting platelet aggregation in patients with acute coronary syndrome.
DESIGN, SETTING, PARTICIPANTS AND INTERVENTIONS: A total of 64 patients from Yueyang Hospital of Traditional Chinese and Western Medicine affiliated to Shanghai University of Traditional Chinese Medicine were randomly divided into Honghua Injection group (n=32, routine Western medicine plus Honghua Injection) and control group (n=32, routine Western medicine) according to the random number table. The patients were treated for 14 d.
MAIN OUTCOME MEASURES: The expressions of GPⅡb/Ⅲa (CD41), P-selection (CD62p), and lysosome-associated membrane GP (CD63) were measured by flow cytometry before and after treatment. Meanwhile the therapeutic effects of Huonghua Injection on angina and short-term prognosis were observed.
RESULTS: The observational period was 14 d and four patients in the control group were omitted due to early discharge. The expression of CD41 in both the Honghua Injection group and the control group was inhibited after treatment (P<0.05, P<0.01). The inhibition of the Honghua Injection group was stronger than that of the control group (P<0.05). There was no case of death, myocardial infarction and cerebral apoplexy during 14 d of treatment. The improvement of angina symptoms and electrocardiographic manifestation in the Honghua Injection group was greater than that of the control group (P<0.05).
CONCLUSION: Honghua Injection can inhibit the expression of GPⅡb/Ⅲa receptors by preventing aggregation of platelets and may be considered as an effective traditional Chinese medicine for acute coronary syndrome.
Welcome to JIM! You are the number 7139 reader of this article!
Download Article:
[Full Text]      [PDF]      [Previous]      [Next]      [This Issue]
Please cite this article as:
Zhu YF, Luo HM, Deng ZL, Fu DY, Yao W, Dai J. Effects of the Chinese patent medicine, Honghua Injection, on platelet glycoprotein Ⅱb/Ⅲa receptors in patients with acute coronary syndrome: a randomized controlled trial. J Chin Integr Med / Zhong Xi Yi Jie He Xue Bao. 2012; 10(3): 318-323.
References:
1Xu DM, Jin Y, Xu WP. Carthamus tinctorius injection in treating stable angina pectoris[J].Zhongguo Xin Yao Yu Lin Chuang Za Zhi, 2003, 22(1): 13-15. Chinese with abstract in English
2Li JJ, Jiang LJ, Hou YL, Liang HF, Zhao ZG. Characteristics of erythrocyte rheology in patients with coronary atherosclerotic heart disease after Honghua injection[J].Zhongguo Zu Zhi Gong Cheng Yan Jiu Yu Lin Chuang Kang Fu, 2007, 11(20): 3912-3915. Chinese with abstract in English
3Xu KL, Fan HC, Shen WY, Huang TQ, Liu LM. Clinical treatment of cerebral infarction by Safflower Injection via carotid artery infusion[J].Zhong Cheng Yao, 2005, 27(6): 678-681. Chinese with abstract in English
4Guo ML, Zhang G, Zhang W, Zhang HM, Su ZW. Determination of safflor yellow A by RP-HPLC and resources quality comparison in Carthamus tinctorius[J].Zhongguo Zhong Yao Za Zhi, 2006, 31(15): 1234-1236. Chinese with abstract in English
5Guo ZQ, Cheng Z, Li L, Liu QY, Wu HB, Gu Y. Effect of administration of Safflower yellow injection on the platelet aggregate rate and transforming growth factor-β1 in patients without ST elevation acute myocardial infarction[J].Lin Chuang Xin Xue Guan Bing Za Zhi, 2010, 26(8): 591-593. Chinese with abstract in English
6Xia YY, Min Y, Sheng YC. The effects of hydroxysafflor yellow A on the formation of thrombus and platelet aggregation in rats[J].Zhongguo Yao Li Xue Tong Bao, 2005, 21(11): 1400-1401. Chinese with abstract in English
7Rossi F, Rossi E, Pareti FI, Colli S, Tremoli E, Gallo L. In vitro measurement of platelet glycoprotein Ⅱb/Ⅲa receptor blockade by abciximab: interindividual variation and increased platelet secretion[J].Haematologica, 2001, 86(2): 192-198.  
8Wang JY. Internal medicine[M]. Beijing: People’s Medical Publishing House, 2005. 276-278. Chinese
9Evaluation criteria for the curative effects of angina pectoris due to coronary heart disease and electrocardiographic manifestation (Passed by the Symposium on Treatment of Angina Pectoris of Coronary Heart Disease and Arrhythmia, 1979, Shanghai). Zhongguo Yao Shi. 1987; 1(1): 71. Chinese.
10Xu JF, Chen GF, Li ZL, Chen H. Antiplatelet and anticoagulant therapy for acute coronary syndrome[J].Yi Xue Zong Shu, 2010, 16(16): 2479-2482. Chinese with abstract in English
11Li XF, Jiang YR, Gao ZY, Yin HJ, Chen KJ. Screening, identification and analysis of platelet differential functional proteins in patients with coronary heart disease of blood-stasis pattern[J].Zhongguo Zhong Xi Yi Jie He Za Zhi, 2010, 30(5): 467-473. Chinese with abstract in English
12EPISTENT Investigators. Randomised placebo-controlled and balloon-angioplasty-controlled trial to assess safety of coronary stenting with use of platelet glycoprotein-Ⅱb/Ⅲa blockade[J].Lancet, 1998, 52(9122): 87-92.  
13Maia F, Sá FC, Feres F. Glycoprotein Ⅱb/Ⅲa inhibitors in clinical practice[J].Arq Bras Cardiol, 2009, 92(1): 68-76.  
 Home | Current Issue | Past Issues | SearchRSS
Copyright © 2013-2018 by JIM Editorial Office. All rights reserved. ISSN 2095-4964; CN 31-2083/R. 沪ICP备110264号